search
Back to results

Toxoplasmic Encephalitis in Patients With AIDS. Treatment and Prevention of Relapse

Primary Purpose

Toxoplasmosis, Cerebral, HIV Infections

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Pyrimethamine
Clindamycin
Sponsored by
Palo Alto Medical Foundation
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Toxoplasmosis, Cerebral focused on measuring Sulfonamides, Toxoplasmosis, AIDS-Related Opportunistic Infections, Pyrimethamine, Drug Therapy, Combination, Encephalitis, Acquired Immunodeficiency Syndrome, Clindamycin

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Exclusion Criteria Co-existing Condition: Patients with the following conditions are excluded: Opportunistic infection (Pneumocystis carinii pneumonia (PCP), cryptococcal meningitis) or other conditions (brain abscess) which would make treatment results difficult to interpret due to concurrent infection, disease, or therapy. Patients with other opportunistic infections or brain diseases are excluded. Patients with AIDS and cerebral toxoplasmosis.

Sites / Locations

  • Palo Alto Med Foundation

Outcomes

Primary Outcome Measures

Secondary Outcome Measures

Full Information

First Posted
November 2, 1999
Last Updated
June 23, 2005
Sponsor
Palo Alto Medical Foundation
search

1. Study Identification

Unique Protocol Identification Number
NCT00002064
Brief Title
Toxoplasmic Encephalitis in Patients With AIDS. Treatment and Prevention of Relapse
Official Title
Toxoplasmic Encephalitis in Patients With AIDS. Treatment and Prevention of Relapse
Study Type
Interventional

2. Study Status

Record Verification Date
June 1989
Overall Recruitment Status
Completed
Study Start Date
undefined (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
Palo Alto Medical Foundation

4. Oversight

5. Study Description

Brief Summary
To compare pyrimethamine and intravenous (IV) clindamycin vs. pyrimethamine and sulfonamides in the treatment of AIDS patients with central nervous system (CNS) Toxoplasma gondii.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Toxoplasmosis, Cerebral, HIV Infections
Keywords
Sulfonamides, Toxoplasmosis, AIDS-Related Opportunistic Infections, Pyrimethamine, Drug Therapy, Combination, Encephalitis, Acquired Immunodeficiency Syndrome, Clindamycin

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Pyrimethamine
Intervention Type
Drug
Intervention Name(s)
Clindamycin

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Exclusion Criteria Co-existing Condition: Patients with the following conditions are excluded: Opportunistic infection (Pneumocystis carinii pneumonia (PCP), cryptococcal meningitis) or other conditions (brain abscess) which would make treatment results difficult to interpret due to concurrent infection, disease, or therapy. Patients with other opportunistic infections or brain diseases are excluded. Patients with AIDS and cerebral toxoplasmosis.
Facility Information:
Facility Name
Palo Alto Med Foundation
City
Palo Alto
State/Province
California
ZIP/Postal Code
94301
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Toxoplasmic Encephalitis in Patients With AIDS. Treatment and Prevention of Relapse

We'll reach out to this number within 24 hrs